Bulletin from the Annual General Meeting in CELLINK AB (publ)

At the Annual General Meeting of CELLINK AB (publ) (the “Company”), held on 18 December 2019, the following resolutions were passed regarding the financial year 1 September 2018 – 31 August 2019.

  • The Annual General Meeting resolved to adopt the income statement and balance sheet, consolidated income statement and balance sheet for the financial year 2018/2019 as well as that the Company’s results shall be carried forward and thus no dividend will be distributed.
  • The Annual General Meeting resolved to discharge the members of the Board of Directors and Chief Executive Officer from liability.
  • The Annual General Meeting resolved that the members of the Board of Directors shall be seven with no deputy members.
  • The Annual General Meeting resolved on the fees for the Board of Directors and the auditor, in accordance with the Nomination Committees’ proposal.
  • The Annual General Meeting resolved, in accordance with the Nomination Committees’ proposal, that Carsten Browall, Artur Aira, Ingela Hallberg, Bengt Sjöholm and Erik Gatenholm are re-elected as members of the Board of Directors and that Christian Wildmoser and Helena Skåntorp would be elected as new members of the Board of Directors, for the period until the end of the next Annual General Meeting.
  • The Annual General Meeting resolved to re-elect Deloitte AB as audit firm, with Fredrik Jonsson as the auditor in charge, for the period until the end of the next Annual General Meeting.
  • The Annual General Meeting resolved that the principles for appointment of the nomination committee as approved by the annual general meeting 2018 shall remain unchanged until the end of the next Annual General Meeting.
  • The Annual General Meeting resolved to approve the proposed guidelines for remuneration for executive management.
  • The Annual General Meeting resolved, in accordance with the Board of Directors’ proposal, to adopt new Articles of Association, in part to enable the split of the Company’s shares and to enable future new issues as well as to change the Company’s financial year to calendar year.
  • The Annual General Meeting resolved, in accordance with the Board of Directors’ proposal, on a split of the Company’s shares, meaning that each share, regardless of class of share, is divided into four shares (share split 4:1).
  • The Annual General Meeting resolved, in accordance with the Board of Directors’ proposal, to adopt a new long-term incentive programme for employees within the CELLINK group (the “Warrant programme 2019”) through a directed issue of a maximum of 1,600,000 warrants.
  • The Annual General Meeting resolved, in accordance with the proposal from some of the Company’s large shareholders, to adopt a new long-term incentive programme for the Chairman of the Board and other ordinary Board members (“LTIP 2019”) through a directed issue of a maximum of 220,000 warrants.
  • The Annual General Meeting resolved, in accordance with the Board of Directors’ proposal, to authorise the Board of Directors to, with or without deviation from the shareholders’ preferential rights, resolve on a new issue of shares of series B, warrants and/or convertibles that entitles to new shares of series B.

Approximately 84,81% per cent of the votes were represented at the Annual General Meeting.

For further information, please contact:

Erik Gatenholm, CEO                                                                    Gusten Danielsson, CFO

Phone: EU +46 73 267 00 00                                                        Phone: +46 70 991 86 04
US +1 (650) 515 5566                                                                  US +1 (857) 332 2138

Email: eg@cellink.com                                                                   Email: gd@cellink.com

Important information

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

About CELLINK

CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at certifiedadviser@penser.se.

at: certifiedadviser@penser.se.

Latest press releases
November 14, 2019Annual Report 2018/2019